
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is well-positioned as a leading pharmaceutical company with a strong portfolio including Keytruda and Gardasil, and a promising pipeline that includes potential blockbuster drugs such as Islatravir + Lenacapavir for HIV and enlicitide for PCSK9 inhibition. The upcoming catalysts, such as data readouts from Trop-2 sac-TMT and Phase 3 trials for tulisokibart, provide potential for further upside. The company also has a strong presence in the pediatric vaccine market and animal health industry, diversifying its revenue streams.
Bears say
Merck & Co is facing potential challenges in its revenue growth due to several factors, including a negative outlook on Keytruda, potential product failure in clinical trials, and risks related to generic or biosimilar competition. The company's recent acquisition of Terns Pharma may also have a negative impact in the short term, as reflected in its 2Q earnings with a $5.8B charge. However, the company has a strong portfolio of products in various therapeutic areas and may have potential for growth in the future, though this growth may be underappreciated by investors. The company also faces risks related to macroeconomic conditions and potential delays or rejections for approval of investigational assets.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares